SCHEMBL95283

SCHEMBL95283

[CH2]c1ccc(C(=O)NCc2ccc(F)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.67
LMNA P02545 5/20 0.66
CXCR4 P61073 1/20 0.58
CYP3A4 P08684 1/20 0.57
MAPK14 Q16539 1/20 0.57
KMT2A Q03164 3/20 0.55
MEN1 O00255 2/20 0.55
EPHX2 P34913 1/20 0.54
PPARG P37231 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
POLB P06746 1/20 0.53
HDAC6 Q9UBN7 2/20 0.53
HDAC1 Q13547 1/20 0.53
HDAC3 O15379 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C19 P33261 1/20 0.53
ALDH1A1 P00352 1/20 0.52
ALOX12 P18054 1/20 0.52
RECQL P46063 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6077802 0.91 L3MBTL1 (0.77) L3MBTL1LMNACXCR4CYP3A4MAPK14
SCHEMBL6569859 0.85 HDAC6 (0.73) L3MBTL1LMNACXCR4CYP3A4MAPK14
SCHEMBL10099566 0.85 NR1H4 (0.69) L3MBTL1LMNACXCR4CYP3A4MAPK14
SCHEMBL3455449 0.85 L3MBTL1 (0.69) L3MBTL1LMNACXCR4CYP3A4MAPK14
SCHEMBL8429875 0.83 LMNA (0.70) L3MBTL1LMNACXCR4CYP3A4MAPK14
SCHEMBL6357065 0.83 LMNA (0.70) L3MBTL1LMNACXCR4MAPK14KMT2A
SCHEMBL19630565 0.83 EPHX2 (0.68) L3MBTL1LMNACXCR4CYP3A4MAPK14
SCHEMBL95043 0.83 MEN1 (0.68) CYP3A4MAPK14KMT2AMEN1EPHX2
SCHEMBL10099594 0.83 LMNA (0.70) L3MBTL1LMNACXCR4MAPK14KMT2A
SCHEMBL6355362 0.83 POLB (0.72) L3MBTL1LMNACXCR4CYP3A4MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
CN-101489555-A Nf-kappa OTSUKA PHARMA CO LTD (JP) 2009-07-22 CN disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB L3MBTL1 1099/4885LMNA 3740/4885CXCR4 1485/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 L3MBTL1 262/4885LMNA 4860/4885CXCR4 464/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 L3MBTL1 262/4885LMNA 4860/4885CXCR4 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.